Astana Biomed Group, an authorized Abcam distributor in Central Asia

Human KIF20A knockout HEK-293T cell lysate (ab263241)

Overview

  • Product name

    Human KIF20A knockout HEK-293T cell lysate

  • Product overview


    Knockout cell lysate achieved by CRISPR/Cas9.

  • Parental Cell Line

    HEK293T

  • Organism

    Human

  • Mutation description

    Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 2.

  • Passage number

  • Knockout validation

    Sanger Sequencing

  • Reconstitution notes

    To use as WB control, resuspend the lyophilizate in 50 µL of LDS* Sample Buffer to have a final concentration of 2 mg/ml. For reducing conditions, we recommend a final concentration of 0.1 M DTT.

    *Usage of SDS sample buffer is not recommended with these lyophilized lysates.

  • Notes

    Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version - found here. Please refer to our lysis protocol for further details on how our lysates are prepared.

    User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

    Access thousands of knockout cell lysates, generated from commonly used cancer cell lines.
    See here for more information on knockout cell lysates.

    Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
    It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

    This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Properties

Target

  • Function

    Mitotic kinesin required for chromosome passenger complex (CPC)-mediated cytokinesis. Following phosphorylation by PLK1, involved in recruitment of PLK1 to the central spindle. Interacts with guanosine triphosphate (GTP)-bound forms of RAB6A and RAB6B. May act as a motor required for the retrograde RAB6 regulated transport of Golgi membranes and associated vesicles along microtubules. Has a microtubule plus end-directed motility.

  • Sequence similarities

    Belongs to the kinesin-like protein family.
    Contains 1 kinesin-motor domain.

  • Post-translational
    modifications

    Phosphorylated by PLK1 at Ser-528 during mitosis, creating a docking site for PLK1 and recruiting PLK1 at central spindle.

  • Cellular localization

    Golgi apparatus. Cytoplasm > cytoskeleton > spindle.
  • Information by UniProt

  • Alternative names

    • AA415432
    • FLJ21151
    • GG10 2
    • GG10_2
    • KI20A_HUMAN
    • KIF20A
    • kinesin family member 20A
    • Kinesin like protein KIF20A
    • Kinesin-like protein 174
    • Kinesin-like protein KIF20A
    • mitotic kinesin like protein 2
    • Mitotic kinesin-like protein 2
    • MKlp2
    • OTTHUMP00000159481
    • RAB6 interacting, kinesin like (rabkinesin6)
    • Rab6-interacting kinesin-like protein
    • RAB6-INTERACTING PROTEIN, KINESIN-LIKE
    • RAB6KIFL
    • Rabkinesin 6
    • Rabkinesin-6
    see all

Properties

Images

  • Sanger Sequencing - Human KIF20A knockout HEK293T cell lysate (ab263241)
    Sanger Sequencing - Human KIF20A knockout HEK293T cell lysate (ab263241)
    Homozygous: Insertion of the selection cassette in exon 2

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up